Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Press Releases

Keyword Search

October 23, 2019
Ocugen Appoints Jessica Crespo, CPA, as Controller
MALVERN, Pa., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of
Additional Formats
PDF Version
October 9, 2019
Ocugen Announces Share Repurchase Program
MALVERN, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) today announced that its Board of Directors unanimously approved a share repurchase program authorizing the repurchase of up to $2 million in value of its outstanding common stock.  Ocugen believes its shares are
Additional Formats
PDF Version
October 7, 2019
Ocugen Announces Amendment to Asset Purchase Agreement
Restructured terms increase value to Ocugen MALVERN, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye
Additional Formats
PDF Version
October 1, 2019
Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer
MALVERN, Pa., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of
Additional Formats
PDF Version
September 30, 2019
Ocugen to Present at Three Upcoming Conferences
MALVERN, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that Shankar Musunuri,
Additional Formats
PDF Version
September 30, 2019
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
  MALVERN, Pa. --(BUSINESS WIRE)--Sep. 30, 2019-- Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on innovative therapies that address rare and underserved eye diseases, today announced the completion of its merger with Histogenics Corporation (previously NASDAQ:
Additional Formats
PDF Version
April 8, 2019
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
— Conference call to be held today at 8:30 a.m. Eastern Time — BOSTON, Mass. and MALVERN, Penn., April 08, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused on discovering, developing and
Additional Formats
PDF Version